Hepatitis C virus therapeutic development: in pursuit of "perfectovir". (Q38374284)

2 September 2017

1 reference

title

Hepatitis C virus therapeutic development: in pursuit of "perfectovir". (English)

1 reference

2 September 2017

1 reference

1 reference

1

Gregory J Dore

1 reference

2 September 2017

Jordan J Feld

2

1 reference

2 September 2017

language of work or name

English

0 references

publication date

11 March 2015

1 reference

Clinical Infectious Diseases

2 September 2017

published in

1 reference

2 September 2017

volume

60

1 reference

2 September 2017

issue

12

1 reference

2 September 2017

page(s)

1829-1836

1 reference

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV197

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV197

Telaprevir for previously untreated chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV197

Boceprevir for untreated chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV197

Breaking down the barriers to hepatitis C virus (HCV) treatment among individuals with HCV/HIV coinfection: action required at the system, provider, and patient levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV197

Barriers associated with the treatment of hepatitis C virus infection among illicit drug users.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV197

Overcoming barriers to care for hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV197

Low virological response and high relapse rates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic dosing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV197

New direct-acting antivirals' combination for the treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV197

The hepatitis C virus life cycle as a target for new antiviral therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV197

Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV197

Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV197

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV197

Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV197

ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV197

Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV197

ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV197

Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV197

Curing hepatitis C with pills: a step toward global control

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV197

A Canadian screening program for hepatitis C: is now the time?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV197

Outcomes of treatment for hepatitis C virus infection by primary care providers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV197

Delivery of treatment for hepatitis C virus infection in the primary care setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV197

Assessment and treatment of hepatitis C virus infection among people who inject drugs in the opioid substitution setting: ETHOS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV197

Enhancing assessment and treatment of hepatitis C in the custodial setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV197

Epidemiology and natural history of HCV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV197

The epidemiology of hepatitis C virus in Egypt: a systematic review and data synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV197

Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV197

HIV infection: epidemiology, pathogenesis, treatment, and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV197

21 January 2018

Identifiers

DOI

10.1093/CID/CIV197

1 reference

2 September 2017

1 reference